# Resolution ctDx FIRST

Source: https://onco.cc/drugs/resolution-ctdx-first/  
OnCo record `resolution-ctdx-first` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.

## Summary

Agilent's Resolution ctDx FIRST was approved by the FDA in December 2022 alongside adagrasib as a liquid biopsy companion diagnostic for KRAS G12C-mutant non-small-cell lung cancer, with tumour-profiling claims for other lung cancer genes. It is the second liquid comprehensive genomic profiling test with a companion claim after Guardant360 CDx and FoundationOne Liquid CDx. As with all plasma tests, a negative result should be followed by tissue testing.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: test
- Brand: Resolution ctDx FIRST
- Modality: Liquid biopsy companion diagnostic test (NGS, cfDNA)
- Mechanism: Targeted NGS of plasma cell-free DNA covering lung cancer driver genes, with a companion claim for KRAS G12C.
- Approvals: US 2022: Companion diagnostic for adagrasib in KRAS G12C-mutant NSCLC (plasma)

## Notes

- What a result means: KRAS G12C detected in blood makes adagrasib or sotorasib an option after first-line treatment.

## Sources

- Agilent: Resolution ctDx FIRST: https://www.agilent.com/en/product/liquid-biopsy/resolution-ctdx-first

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/)
- companies: [Agilent Technologies (Dako)](https://onco.cc/companies/agilent/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/)

---
JSON: https://onco.cc/api/v1/entities/resolution-ctdx-first.json